Affiliation:
1. Division of Gastroenterology and Hepatology, Saitama Children’s Medical Center , Saitama , Japan
Abstract
Lay Summary
We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.
Publisher
Oxford University Press (OUP)
Reference9 articles.
1. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease;Kelsen;J Pediatr Gastroenterol Nutr.,2020
2. Efficacy and safety of anti-tumor necrosis factor alpha in very early onset inflammatory bowel disease;Collen;Inflamm Bowel Dis.,2023
3. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID;Koudsi;J Pediatr Gastroenterol Nutr.,2023
4. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study;Rosh;J Crohns Colitis.,2021
5. Experience using ustekinumab in pediatric patients with medically refractory Crohn Disease;Kim;J Pediatr Gastroenterol Nutr.,2021